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Historical Perspective on Non-Communicable Diseases
Worldwide
The blooming of incidence and prevalence of “prosperity diseases” among the broad layers of
modern day populations is rather novel phenomenon in demographic history of the human race
(1). Illnesses such as obesity (2), diabetes mellitus, hypertension, cerebrovascular and cardiovascular
consequences of atherosclerosis, renal insufficiency, mental disorders, and even cancer are closely
related to the increased longevity of most contemporary societies (3). In previous centuries, they
were mostly reserved for elite social groups enjoying rather luxurious life style. Vast majority of
citizens of the time were living in rural communities on the verge of poverty. Their structure of
morbidity even in Europe until late 19th century was dominated by burden of infectious diseases
and injury while neonatal and maternal mortality rates were huge. Industrial revolution led to the
growth of living standards, invention of vaccines, and antibiotics, and ultimately development of
organized publicly funded health systems. The prominent European health policy makers in the
19th century properly believed that effective public health measures will diminish huge burden
of infectious diseases. Consecutively, they expected that overall costs of medical care provision
should decrease substantially and ultimately reach plateau level. This second step turned out
to be a great miscalculation and a surprise. Like no time in written past, people began living
longer and healthier lives. But it happened at the cost. Simultaneously, from many industrialized
nations, evidence were accumulating of accelerated occurrence of non-communicable diseases.
Accomplishment of evidence-based medicine succeeded to control many of these initially incurable
diseases, thereby transforming them into life time disorders as in the typical cases of diabetes
and terminal renal insufficiency. Acute bacterial infections, dominating morbidity in the old days,
were usually successfully treated within few weeks. Unlike these, chronic illnesses were bringing
long-term burden for both the patients and the society. Malignant disorders with its complex
treatment strategies present particularly demanding medical conditions. Cancer leaves permanent
footprint in a life of a patient in terms of poor survival rates, decreased life quality, and working
ability.
Non-Communicable Diseases Expansion in Developing Countries
The ultimate demographic transition consisting of ascending portion of elderly, falling fertility
rates, and bold growth of median age within contemporary nations became broadly recognized as
population aging (4). Most of this transformation of morbidity and mortality structure happened
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in rich industrial countries of Western Europe, North America,
and Japan many decades ago. The same pattern of population
aging associated with huge incidence and prevalence rates of
major non-communicable diseases repeated on wider scale much
later in developing countries. The worldwide transformation of
public health landscape to the large extent is attributable to the
accelerated pace of globalization after the end of Cold War era
(5). Particularly interesting, current developments belong to the
economies responsible for most of global growth that are recog-
nized as the emerging markets. The countries whose reshaped
structure of morbidity is most likely to affect global health in
the future are definitely the BRICS [Brazil (6), Russia, India,
China, South Africa] (7). BRICS’s far extended long-term influ-
ence in health arena worldwide will be related to their mam-
moth sized populations. Their increased domestic demand for
medical technologies and medicines is already shaping invest-
ment strategies of major pharmaceutical and medicinal device
industries. Another significant issue is their bold foreign medical
assistance programs particularly targeted for emerging markets
of Sudanese Africa, Latin America, Central and South East Asia
(8). These leading countries are closely followed by a set of
smaller scale economies mostly marked as N-11 (Bangladesh,
Egypt, Indonesia, Iran, South Korea, Mexico, Nigeria, Pakistan,
the Philippines, Turkey, and Vietnam) (9). Very similar process is
simultaneously taking place in dynamically developing Southern
(10) and South-East Asian (11), Latin American, Eastern Euro-
pean (12), and Arab speaking MENA region (13). Eradication
of poverty currently taking place in these regions is coupled
with changed dietary habits (14) (higher salt and fat and lower
carbohydrate intake), wide spread tobacco abuse, and sedentary
life styles (15). The mentioned factors contributing to the grow-
ing burden of non-communicable diseases. It became obvious
that contribution of emerging markets and Third World coun-
tries to the global economic burden of NCDs will grow further.
It will, highly, likely, soon have greater share than the one of
established mature market economies (16). As basic assump-
tion of most forecasts remains the fact that such growth will
be dominated by developments in China (17) and India (18).
High toll of this unfortunate change for developing countries is
coupled impact of communicable and non-communicable dis-
eases (19). At the same time, many national health systems
throughout Asia and beyond expose poor responsiveness to
the NCDs related population needs. There seems to be serious
barriers in access to medical care and its affordability to the
ordinary citizens.
The increasing awareness on approaching of almost unbearable
burden of NCDs (20) led to the high profile United Nations
meeting on the subject in 2011 (21). Such UN gatherings are
so uncommon on health related topics that it happened only
once in past due to AIDS. NCDs recognized as the core global
health challenges were cardiovascular disorders, cancer, diabetes,
and chronic respiratory illness. These changes are beginning to
profoundly change the landscape of even the poorest countries
around the globe. So far, NCDs have already overarched burden
of infectious diseases and injury in terms of disability adjusted
life years, as well as work load and economic burden to the most
national health sectors (22).
Promising Cost-Effective Solutions for the
Future
The blossoming of prosperity disease did not happen suddenly.
It was a consequence of long chain of evolutionary events in
civil society development. We will mention only some of them
such as technological revolution, improved housing conditions,
sanitation and sewage disposal, public health successes in erad-
ication of major infectious diseases, policy efforts to tackle
hunger and starvation among the world’s poor, and ultimately
tobacco (23) and alcohol abuse (24). As its preconditions took
so long to be created, it is unlikely that we shall be able to
tackle NCD’s burden effectively in near future. Rich countries
as well as developing ones concluded that orchestrated efforts
will be needed in the international arena. World Health Orga-
nization has adopted a package of measures, whose implemen-
tation and progress are being monitored (25), broadly known
as “Global coordination mechanisms on NCDs” (26). As most
cost-effective and feasible measures were identified, control of
tobacco consumption to the targeted 5% consumers worldwide
until 2025 and reduction of salt intake by general populations
of at least 15% in the order of significance. These interven-
tions that were named “best buy” solutions offering best attain-
able compromise between the need for investment and out-
comes that will be gained (27). Promotion of active life style
and healthy diet, as well as other preventive and screening mea-
sures, comes at the second place. If such efforts are followed
closely by national authorities, WHO expects that these mea-
sures should achieve 25% reduction of NCD attributable prema-
ture mortality until 2025 (28). Many of the proposed strategies
were previously tested within a sound methodological framework
applied on a second largest emerging market of the America,
Mexico (29).
The most challenging issue for the emerging markets’ health
systems appears to be universal health coverage (30). These sys-
tems were built up on diverse historical legacies and should find
each one its own way to handle the upcoming pressure of prosper-
ity diseases coupled with accelerated population aging. Profound
transformation of current network of medical facilities in Third
World countries, as well as human capacity building, will be
forced to move priority from acute care toward complex, chronic
illnesses (31).
Growing Burden of NCDs Coincided with
Increasing Health Expenditures
As witnessed by current WHO estimates given in Table 1, we
may see that overall burden of non-communicable disease has
consolidated in some countries such as Russia recording even
slight decrease over the past decade. Nevertheless, leading emerg-
ing markets of China and India followed by a large distance in
absolute terms by Brazil and South Africa exhibited clear pattern
of increasing burden of NCDs expressed in terms of Years of
Life Lost, Years Lost due to Disability, and Disability-Adjusted
Life Year (DALY). According to WHO, NCDs attributable mor-
tality increased substantially among the same four countries with
notable promising exception of Russia. Russian partial success
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TABLE 1 | Non-communicable diseases burden-related indicators; WHO estimates for BRICS in 2000 and 2012; total health expenditure and out-of-pocket
health expenditure in terms of current international $ purchase power parity basis (source: Global Health Expenditure Database).
Brazil Russian
federation
India China South Africa
2000 2012 2000 2012 2000 2012 2000 2012 2000 2012
Population (millions) 174.5 198.6 146.8 143.2 1,042.3 1,236.7 1,287.7 1,384.8 44.8 52.4
Years of Life Lost [YLL (0000)]* 22,532 24,915 44,566 40,597 150,751 175,435 165,905 186,591 5,534 7,398
Years Lost due to Disability [YLD
(0000)]**
14,600 18,077 16,586 16,206 78,150 96,886 84,450 99,877 3,436 4,233
Disability-Adjusted Life Year [DALY
(0000)]***
37,132 42,992 61,152 56,803 228,901 272,321 250,355 286,468 8,970 11,631
Estimated deaths (0000) NCDs
caused, both sexes
777 978 1,819 1,801 4,579 5,869 6,839 8,577 176 264
Total expenditure on health (in million
current $ PPP)
$87,681 $220,240 $54,200 $211,008 $68,816 $193,969 $138,131 $664,644 $24,728 $51,458
Out of pocket expenditure (in million
current $PPP)
$33,277 $68,168 $16,242 $72,417 $46,771 $111,673 $81,469 $228,245 $3,227 $3,695
*WHO estimated Years of Life Lost (YLL) due to premature mortality NCDs caused, both sexes (0000).
**WHO estimated Years Lost due to Disability (YLD) for people living with NCDs or its consequences (0000).
***WHO estimated Disability-Adjusted Life Year (DALY) NCDs caused, both sexes (0000).
in containing but not decreasing toll of prosperity diseases over
2000–2012 observation period might be attributable to the strong
public health legacy of Soviet era as well as reform policies
implemented in recent past (32). The rates of hospital discharges
increased substantially in the emerging markets across the globe
following the increased presence of NCDs in the overall mor-
bidity and mortality structure. This was mainly the case with
clinical admissions that could be attributed to the malignant
disorders (33) and circulatory diseases (34), followed by chronic
obstructive pulmonary diseases (35) and diabetes (36). National
level spending on medicines indicated to treat these conditions
followed at the same pace, so entire regional pharmaceutical
markets adjusted to these changes as was the case in South
Eastern Europe (37). Extensive presence of chronic prosperity
illnesses supported stronger demand for medical imaging (38),
laboratory testing (39), outpatient visits, prescription and dispens-
ing of novel pharmaceuticals (40), surgical, radiation oncology
(41), and rehabilitation services. These phenomena were relying
on strengthened civil expectations for advanced medical tech-
nologies supported by growing living standards and domestic
consumption in BRICS markets. If we take into account seri-
ous challenge of home-based care for the disabled and growing
portion of elderly citizens with special needs, bold growth of
national health expenditures should have been predicted (42).
China is absolutely leading in terms of purchase power parity
of its health spending. Huge lag of all other major emerging
economies behind People’s Republic of China is most obvious
when compared to the India, rapidly developing nation of a similar
population size.
Catastrophic household expenditure presents particularly cru-
cial issue throughout the countries of Sudanese Africa with very
low incomes, whose medical care is dominantly supported by
out-of-pocket spending (43). This happens due to absence of
strong national health insurance funds whose revenues would
come out of mandatory taxation supported by governmental and
external financial sources. Huge, occasionally sevenfold growth of
out-of-patient expenditure is clearly visible among the top BRICS
markets. Such socioeconomic vulnerability seriously affects the
poor members of the community. This might be the crucial
issue for long-term affordability (44) of medical care to the ordi-
nary citizens because almost all of the emerging markets own
massive rural populations. Urbanization process, which began
in Europe in 18th century, is still rapidly evolving throughout
Asia, Africa, and Latin America (45). Extensive development of
medical facilities network covering remote areas will remain one
of the key difficulties for national governments. This is worsened
by inevitable concentration of most professional staff in large
cities with much more rewarding personal career opportunities.
The primary goal for the future of these health systems wiil
be provision of accessible medical care. It should have decent
quality supported by universal health insurance coverage and
full reimbursement of at least essential medicines. The speed of
economic growth, political stability, and effectiveness of health
reforms remain highly diverse among the top 20 emerging mar-
kets. Some global forecasting agencies as well as international
financial organizations were pointing out that some smaller scale
N-11 economies were top performers on some criteria. Never-
theless, the prevailing consensus is that BRICS (46) health care
markets will inevitably outpace all others and remainwell ahead of
their competition shaping the global health challenges in the first
half of 21st century.
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